NCT04408924 - Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

April 27, 2022

Study Completion Date

June 2, 2023

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG

Abemaciclib

Administered orally

Trial Locations (14)

Institut Paoli-Calmettes, Marseille

Hospital General Universitario Gregorio Maranon, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Institut Claudius Regaud, Toulouse

Centre Leon Berard, Lyon

Hopital Europeen Georges Pompidou, Paris

University of Utah - Huntsman Cancer Institute, Salt Lake City

Gustave Roussy, Villejuif

Seattle Cancer Care Alliance, Seattle

Institut Catala d'Oncologia, L'Hospitalet de Llobregat

Corporacion Sanitaria Parc Tauli, Sabadell

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY